Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis-Reference-Cited by-同舟云学术

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis

Published:2016-10-03 Issue:12 Volume:12 Page:3043-3055
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ruiz-Palacios Guillermo M.¹,Leroux-Roels Geert²,Beran Jiri³,Devaster Jeanne-Marie⁴,Esen Meral⁵,Launay Odile⁶,McElhaney Janet E.⁷,van Essen Gerrit A.⁸,Benoit Anne⁹,Claeys Carine¹⁰,Dewé Walthère¹¹,Durand Christelle¹⁰,Duval Xavier¹²,Falsey Ann R.¹³,Feldman Gregory¹⁴,Galtier Florence¹⁵,Gervais Pierre¹⁶,Hwang Shinn-Jang¹⁷,McNeil Shelly¹⁸,Richardus Jan Hendrik¹⁹,Trofa Andrew²⁰,Oostvogels Lidia¹⁰,

Affiliation:

1. Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, C.P. México City, México

2. Centre for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium

3. Vaccination and Travel Medicine Centre, Hradec Kralove, Czech Republic; and 2nd Faculty of Medicine, Charles University in Prague, Czech Republic

4. Jeanne-Marie Devaster, MD, GSK Vaccines, Rixensart, Belgium

5. Institut für Tropenmedizin, Tübingen, Germany

6. Inserm, CIC 1417 and French Network of Clinical Investigation in Vaccinology (I-REIVAC), France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur, Paris, France

7. HSN Volunteer Association Chair in Geriatric Research, Health Sciences North Research Institute, Sudbury, ON, Canada

8. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

9. Institute of Statistics, Biostatistics and Actuarial Sciences, Université Catholique de Louvain, Louvain-la-Neuve, Belgium

10. GSK Vaccines, Wavre, Belgium

11. GSK Vaccines, Rixensart, Belgium

12. Hôpital Bichat Claude Bernard, GH BICHAT. Paris cedex 18, France; Inserm, CIC 007 for the French Network of Clinical Investigation in Vaccinology (REIVAC), Paris Cedex 18, France

13. University of Rochester Medical Center, Rochester General Hospital, Rochester, NY, USA

14. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States

15. CHRU de Montpellier, Hôpital Saint Eloi, Montpellier, France; Inserm, CIC 1001 for the French Network of Clinical Investigation in Vaccinology (REIVAC), Montpellier, France

16. Q&T Research Sherbrooke, Sherbrooke, QC, Canada

17. Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University School of Medicine, Taipei, Taiwan

18. Queen Elizabeth Health Sciences Centre, Dalhousie University, PCIRN, NACI, CCfV, CAIRE, QEII HSC - VG Site Infectious Diseases, Halifax, Nova Scotia, Canada

19. GGD Rotterdam-Rijnmond, Rotterdam, The Netherlands

20. GSK Vaccines, King of Prussia, PA, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2016.1219809

Reference28 articles.

1. The unmet need in the elderly: Designing new influenza vaccines for older adults

2. Better Influenza Vaccines for Older People: What Will It Take?

3. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review